Kythera Labs

Kythera Labs Competitive Intelligence & Landscape

kytheralabs.com ·

Overview

Kythera Labs Overview

Kythera Labs is a healthcare data technology company founded in 2019 and headquartered in Franklin, Tennessee. The company specializes in developing a data management and analytics platform that processes all types of healthcare data, applying machine learning to identify signals for better decision-making in healthcare organizations (Exa). Its flagship product, Wayfinder, is a cloud-based, healthcare-specific data science platform built on Databricks, designed to integrate, standardize, and enhance healthcare data for actionable insights (kytheralabs.com/about).

Kythera Labs serves a broad target market including hospitals, pharmaceutical companies, healthcare technology firms, and government entities, providing solutions that support clinical, commercial, and operational decision-making. The company's core services include data integration, enrichment, machine learning, and analytics, with a focus on improving patient outcomes and market understanding (Exa). With a team of around 34 employees, Kythera Labs emphasizes trust, innovation, and leveraging real-world data to solve complex healthcare challenges. Its mission centers on enabling healthcare organizations to uncover insights from massive datasets, ultimately fostering more confident and effective healthcare decisions (cbinsights.com).

Kythera Labs

Kythera Labs Weekly Intel Updates

Receive weekly intel updates about Kythera Labs straight to your inbox.

Competitors

Kythera Labs Competitors

Metopio stands out as a key competitor to Kythera Labs with its focus on community health assessments and improvement plans through advanced data analytics solutions. It offers a platform for conducting health assessments and strategic planning, positioning itself strongly in the public health sector (CB Insights). In terms of market positioning, Metopio emphasizes community health and public health analytics, which makes it a specialized alternative to Kythera Labs' broader healthcare data analytics offerings.

Tuva Health is another significant competitor, focusing on claims and medical record data normalization, unification, and quality testing to support analytics and AI development. Its services are tailored toward enabling healthcare organizations to leverage raw data effectively for operational and strategic insights (CB Insights). Compared to Kythera Labs, Tuva emphasizes data quality and AI readiness, with a market position centered on data preparation and enrichment, which complements Kythera’s more comprehensive data integration and analytics platform.

Eccovia is a notable player in healthcare data management, offering solutions that integrate multiple data sources for care coordination, population health, and analytics. Its platform is designed to improve care delivery and health outcomes through data sharing and analytics, making it a direct competitor in the healthcare data infrastructure space (CB Insights). Eccovia's market focus on care coordination and population health management aligns closely with Kythera Labs' mission, but it tends to emphasize care delivery improvements.

In addition, IQVIA is a major player in health analytics with a broad portfolio that includes data, technology, and contract research services. Its market share in health analytics is significant, and it competes with Kythera Labs through extensive data assets and advanced analytics capabilities (6sense). IQVIA’s large scale, global presence, and diverse service offerings give it a competitive edge over smaller firms like Kythera Labs, especially in terms of market share and resource availability. Overall, these competitors differentiate themselves through specialized focus areas, data quality, and scale, shaping a competitive landscape for Kythera Labs in healthcare analytics.

Product & Pricing

Kythera Labs Product and Pricing Intelligence

Kythera Labs offers a comprehensive healthcare data and product intelligence platform that focuses on delivering analysis-ready and AI-ready healthcare datasets. Their solutions include purpose-built datasets such as diagnostic, patient journey, and chronic conditions data, designed to support strategic decision-making for healthcare providers and life sciences organizations (Kythera Labs).

Regarding pricing, Kythera Labs emphasizes transparency and flexible deployment options, including SaaS and data analysis platforms like Wayfinder, which facilitate secure data access and integration. While specific pricing tiers or plans are not detailed in the available sources, Kythera Labs' offerings are tailored to organizational needs, supporting both small teams and large enterprises with scalable data solutions (Kythera Labs) and strategic partnerships that enhance data utilization (Kythera Labs).

Recent developments highlight their focus on transforming complex healthcare data into actionable insights, with partnerships like HPC to improve price transparency and market analysis, and technological innovations such as Delta Sharing to reduce costs and improve data sharing efficiency (Databricks, Kythera Labs). While exact current pricing plans and tiers are not publicly disclosed, Kythera Labs’ offerings are positioned as flexible, purpose-built solutions designed to meet the complex needs of healthcare data analysis and strategic planning.

Ad Campaigns

Kythera Labs Ad Campaigns

Kythera Labs is currently running 44 ads across LinkedIn — 44 on LinkedIn. Explore Kythera Labs's live ad creative, messaging, and the platforms they advertise on in the ad library — updated automatically by ForesightIQ.

See of Kythera Labs's ads

View ads

Hiring & Layoffs

Kythera Labs Hiring and Layoffs

Kythera Labs has demonstrated a steady growth trajectory, highlighted by recent significant funding and strategic leadership appointments. In November 2023, the company announced a $20 million funding round, which was aimed at accelerating the development and adoption of its Wayfinder data technology platform, supporting its expansion efforts and partnerships with industry leaders like Datavant and Databricks (BioSpace). This funding indicates a strong focus on scaling their healthcare data solutions and expanding their market presence.

Recently, Kythera Labs appointed Glynn Dennis, Jr., Ph.D., as Chief Science Officer in December 2023, emphasizing their commitment to advancing research and development within the life sciences sector (Kythera Labs news). The company’s hiring pattern, which includes executive-level appointments and a focus on expanding their technical and scientific leadership, signals a strategic emphasis on innovation and growth in healthcare data analytics.

Regarding layoffs, there is no publicly available information indicating recent layoffs at Kythera Labs. Their recent activities, including rapid growth, funding, and strategic hires, suggest a company focused on expansion rather than downsizing. Their hiring trends and strategic investments reflect a company positioning itself for long-term growth in healthcare technology and data analytics, aiming to enhance healthcare outcomes and industry partnerships (Tracxn).

Leadership

Kythera Labs Management and Leadership Team

Kythera Labs is led by a team of experienced executives with recent leadership changes and notable hires at the C-suite level. The current CEO and founder is Jeff McDonald, who has a background with companies like Trilliant Health and Deloitte, and has been instrumental in guiding the company's growth (CB Insights). In December 2023, Kythera Labs announced the appointment of Glynn Dennis, Jr. as its new Chief Science Officer (CSO), bringing extensive experience from industry leaders such as AstraZeneca and Genentech, to lead life sciences and pharma initiatives (Kythera Labs news). Additionally, Jay Galbreath serves as the Chief Financial Officer, and Matt Ryan is the Chief Technology Officer, overseeing engineering and technical operations (Equilar).

The leadership team also includes Russ Sacks, Co-Founder and Executive VP of Innovation & Data Science, and Ryan Leurck, Director of Product. The company’s management team is composed of around six key members, with recent hires and leadership roles emphasizing growth in data science, healthcare analytics, and product development (The Org). As of early 2026, Kythera Labs continues to expand its executive team, focusing on strategic growth and innovation in healthcare data analytics (Tracxn).

Financials

Kythera Labs Financial Performance, Fundraising, M&A

Kythera Labs has demonstrated significant growth and activity in recent years, with a notable presence on the 2025 Inc. 5000 list of fastest-growing private companies in America, ranking 38th in the Nashville metro area and 1,945th nationally, reflecting a 54% increase in its ranking (Inc. 5000). Financially, the company has raised a total of approximately $40.86 million over four funding rounds, with the latest Series A - II round closing at $9.19 million on May 29, 2024, and maintaining an estimated valuation of around $9 million (CB Insights, Prospeo). Its revenue for the most recent fiscal year is reported to be around $2.8 million (Prospeo).

Kythera Labs is also actively involved in M&A activities and strategic growth initiatives, including a $20 million funding round announced in November 2023 to accelerate the development of its Wayfinder data platform, which supports healthcare data analytics with over 320 million lives covered (BIP Ventures). The company's financial health indicators, such as its revenue and valuation, suggest a company in growth mode, leveraging substantial funding to expand its data technology offerings and partnerships within the healthcare industry.

Partnerships

Kythera Labs Partnerships, Clients and Vendors

Kythera Labs has established strategic partnerships with leading healthcare analytics firms such as Preverity and GAM, positioning itself as a core data infrastructure provider for healthcare data integration, privacy, and compliance solutions (Kythera Labs). The company is a longstanding Built-On Partner of Databricks, fully integrating with the Databricks Data Intelligence Platform to support high-scale analytics, governed data sharing via Delta Sharing, and enterprise AI workflows, which enhances its ecosystem relationships (Databricks). Notably, Kythera Labs also collaborates with Atropos Health and Scipher Medicine to expand access to real-world data for oncology and autoimmune disease research, respectively, leveraging its high-fidelity datasets and proprietary data transformation technologies (Business Wire, Scipher Medicine). These collaborations underscore Kythera Labs’ role in ecosystem relationships focused on advancing precision medicine and healthcare analytics.

Events

Kythera Labs Event Participations

Kythera Labs actively participates in and hosts a variety of industry events focused on data, AI, and healthcare innovation. Notably, they attended the Databricks Healthcare and Life Sciences Symposium in December 2023, where Jeff McDonald, Kythera Labs CEO, discussed the role of Data and AI in healthcare (source). They also participated in the Databricks Data+AI Summit in July 2024, sharing insights on data governance, AI features, and their impact on healthcare and life sciences (source). Additionally, Kythera Labs is involved in the Data+AI World Tour NYC, where they showcased their innovative data solutions for healthcare and biotech sectors, including talks and booth engagements (source). These events highlight Kythera Labs' commitment to thought leadership and collaboration within the healthcare data and AI community.

Frequently Asked Questions

What does Kythera Labs's December 2023 CSO hire signal about its near-term product and revenue priorities?

The appointment of Glynn Dennis, Jr., Ph.D. — with prior experience at AstraZeneca and Genentech — as Chief Science Officer signals a deliberate pivot toward pharma and life sciences as a primary growth vector. Coupled with the $20 million funding round announced the same month, the hire suggests Kythera Labs is investing in scientific credibility and enterprise sales capacity needed to land large biopharma accounts, not just health system clients.

Does Kythera Labs's funding structure suggest a company on a healthy growth path or one that may be capital-constrained?

The picture is mixed and warrants scrutiny. Kythera Labs has raised approximately $40.86 million across four rounds, including a $20 million round in November 2023 and a follow-on Series A-II of $9.19 million in May 2024 — the latter being a relatively small tranche for a company with that total raise history. Reported annual revenue of roughly $2.8 million implies the company is still pre-scale relative to its capital deployed, and the rapid succession of rounds could indicate ongoing cash needs rather than opportunistic fundraising.

What does Kythera Labs's appearance on the 2025 Inc. 5000 — ranked 1,945th nationally and 38th in Nashville — actually tell a strategic buyer or investor about its growth rate?

The Inc. 5000 ranking confirms multi-year revenue compounding fast enough to clear the list's threshold, but a national rank of 1,945th with a 54% improvement in ranking year-over-year suggests growth acceleration is real yet still modest in absolute dollar terms given ~$2.8 million in reported revenue. For a corp-dev buyer, it signals the company is gaining commercial traction without yet reaching the scale that would make a revenue-based acquisition expensive — a potential window for a deal at favorable multiples.

How does Kythera Labs's partnership with Databricks as a Built-On Partner affect its competitive moat and exposure to platform risk?

The Databricks Built-On partnership deepens Kythera's technical differentiation — Wayfinder is purpose-built on the Databricks Data Intelligence Platform and uses Delta Sharing for governed, cost-efficient data distribution — which should accelerate enterprise sales through Databricks's channel. The flip side is meaningful platform concentration risk: if Databricks shifts partner economics, expands into adjacent analytics offerings, or is acquired, Kythera's product architecture and go-to-market are heavily exposed.

What do Kythera Labs's 2024–2025 partnerships with Atropos Health and Scipher Medicine reveal about its go-to-market strategy shift?

These partnerships mark a deliberate move up the value chain from data infrastructure provider to real-world evidence (RWE) enabler for therapeutic-area research — oncology via Atropos Health and autoimmune disease via Scipher Medicine. Rather than selling horizontal data pipelines, Kythera is embedding its high-fidelity datasets and proprietary transformation technologies into disease-specific research workflows, which implies a strategy of becoming a recurring data supply layer for precision medicine use cases rather than a one-time platform sale.

How does Kythera Labs's competitive position against IQVIA expose it to displacement risk in enterprise accounts?

IQVIA's scale, global data assets, and embedded relationships with large pharma and payer organizations represent a structurally disadvantaged matchup for Kythera in head-to-head enterprise deals. Kythera's realistic competitive angle is speed, flexibility, and Databricks-native architecture for mid-market life sciences and regional health systems that cannot afford or operationalize IQVIA's complexity — but any account that grows to enterprise scale becomes a churn risk as IQVIA and similar players compete on incumbency and breadth.

What does the concentration of Kythera Labs's event presence around Databricks conferences suggest about its channel dependency?

Kythera's visible event footprint — the Databricks Healthcare and Life Sciences Symposium in December 2023, the Databricks Data+AI Summit in July 2024, and the Data+AI World Tour NYC — is almost entirely within the Databricks ecosystem, suggesting the Databricks channel is currently the dominant pipeline-generation mechanism. This creates a concentration risk in lead generation and brand building; Kythera has limited documented presence at independent healthcare IT forums like HIMSS or JPMorgan Healthcare Conference, which could constrain its reach to buyers outside the Databricks orbit.

What does the gap between Kythera Labs's ~$40.86 million in total funding and ~$2.8 million in reported revenue imply about its burn rate and runway considerations?

A cumulative raise of roughly $40.86 million against $2.8 million in annual revenue implies a capital-intensity ratio that is high even by healthcare SaaS standards, suggesting either significant R&D and data infrastructure investment, a long enterprise sales cycle, or both. Without disclosed burn rate data, runway cannot be precisely calculated, but the May 2024 Series A-II follow-on — coming just six months after the $20 million round — raises questions about cash consumption speed that a potential partner or acquirer should diligence closely.

What does hiring Glynn Dennis with an AstraZeneca and Genentech background, rather than a health system or payer background, imply about which customer segment Kythera Labs is prioritizing for revenue growth?

The CSO's biopharma pedigree — AstraZeneca and Genentech specifically — signals that pharma and biotech, not hospitals or payers, are the near-term revenue growth priority. This aligns with the Atropos Health and Scipher Medicine partnership announcements, which target oncology and autoimmune research, and suggests Kythera is positioning Wayfinder as a real-world data platform for drug development and commercialization analytics rather than primarily for health system operations.

How does Tuva Health's focus on data normalization and quality testing position it as a threat to Kythera Labs's core value proposition?

Tuva Health directly challenges the foundational layer of Kythera's offering — claims and medical record normalization and enrichment — which is the prerequisite step before Wayfinder's analytics and ML capabilities can generate value. If Tuva becomes a standard preprocessing layer in enterprise healthcare data stacks, it could commoditize the data preparation work Kythera bundles into its platform, forcing Kythera to differentiate solely on downstream analytics and AI features rather than end-to-end data pipeline ownership.

What does the HPC partnership on price transparency data suggest about Kythera Labs's product expansion strategy beyond clinical analytics?

The partnership with HPC to convert price transparency data into actionable market insights indicates Kythera is deliberately expanding its dataset and use-case coverage into healthcare commercial and financial intelligence — beyond clinical and claims analytics. For a company with a ~34-person team, this breadth-versus-depth trade-off carries execution risk, but it also signals an intent to serve the strategic planning needs of healthcare executives, potentially opening hospital C-suite and payer strategy teams as new buyer personas alongside life sciences customers.

With a team of approximately 34 employees and a CSO, CTO, CFO, and EVP of Innovation on staff, is Kythera Labs's leadership-to-headcount ratio a sign of premature scaling or intentional enterprise positioning?

A six-person executive layer over a ~34-person total headcount — CEO, CSO, CTO, CFO, Co-Founder EVP, and Director of Product — is top-heavy by typical startup benchmarks and likely reflects a deliberate enterprise credentialing strategy rather than operational efficiency. In healthcare data and life sciences, buyers at large pharma and health systems evaluate vendor credibility heavily on executive pedigree, so the investment in named C-suite talent with AstraZeneca, Genentech, Trilliant, and Deloitte backgrounds functions as a sales and partnership enablement asset, even if it compresses margins at current revenue levels.

Powered by ForesightIQ · Competitive intelligence from digital exhaust